vTv Therapeutics
VTVT
41 hedge funds and large institutions have $24.3M invested in vTv Therapeutics in 2016 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 11 reducing their positions, and 8 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 11
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 42 → 41 (-1)
2.75% less ownership
Funds ownership: 51.38% → 48.63% (-2.7%)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
28% less capital invested
Capital invested by funds: $33.9M → $24.3M (-$9.59M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.18M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$525K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$467K |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$340K |
| 5 |
State Street
Boston,
Massachusetts
|
+$37.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$1.13M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.12M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$519K |
| 4 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$500K |
| 5 |
PSC
Piper Sandler & Co
Minneapolis,
Minnesota
|
-$435K |
VTVT Hedge Fund Activity: Q1 2016 in Review
41 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q1 2016, worth a combined $24.3M — down 28% from $33.9M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of VTVT and 7 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 13 added.
The largest buyer was Millennium Management, adding an estimated $1.18M. The largest seller was Farallon Capital Management, cutting an estimated $1.13M.
- 41 institutional investors held vTv Therapeutics (VTVT) as of Q1 2016, down from 42 in Q4 2015.
- Funds reported $24.3M of vTv Therapeutics stock for Q1 2016, down 28% quarter-over-quarter.
- 7 funds opened new vTv Therapeutics positions in Q1 2016 and 8 closed out, a net change of -1 holder.
- The largest vTv Therapeutics buyer in Q1 2016 was Millennium Management, an estimated $1.18M added.
- The largest vTv Therapeutics seller in Q1 2016 was Farallon Capital Management, an estimated $1.13M sold.
Based on aggregated 13F filings for Q1 2016.